209 related articles for article (PubMed ID: 30012889)
1. Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients.
Lattuca B; Belardi D; Demattei C; Schmutz L; Cornillet L; Ledermann B; Macia JC; Iemmi A; Gervasoni R; Roubille F; Cung TT; Robert P; Messner-Pellenc P; Leclercq F; Cayla G
J Invasive Cardiol; 2018 Sep; 30(9):348-354. PubMed ID: 30012889
[TBL] [Abstract][Full Text] [Related]
2. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.
Dworeck C; Redfors B; Angerås O; Haraldsson I; Odenstedt J; Ioanes D; Petursson P; Völz S; Persson J; Koul S; Venetsanos D; Ulvenstam A; Hofmann R; Jensen J; Albertsson P; Råmunddal T; Jeppsson A; Erlinge D; Omerovic E
JAMA Netw Open; 2020 Oct; 3(10):e2018735. PubMed ID: 33001202
[TBL] [Abstract][Full Text] [Related]
3. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Redfors B; Dworeck C; Haraldsson I; Angerås O; Odenstedt J; Ioanes D; Petursson P; Völz S; Albertsson P; Råmunddal T; Persson J; Koul S; Erlinge D; Omerovic E
Eur Heart J; 2019 Apr; 40(15):1202-1210. PubMed ID: 30851037
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
[TBL] [Abstract][Full Text] [Related]
6. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of cangrelor in patients with suboptimal P2Y
Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis.
Dawson LP; Chen D; Dagan M; Bloom J; Taylor A; Duffy SJ; Shaw J; Lefkovits J; Stub D
JAMA Netw Open; 2021 Nov; 4(11):e2134322. PubMed ID: 34797371
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
[TBL] [Abstract][Full Text] [Related]
10. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
Erlinge D; Omerovic E; Fröbert O; Linder R; Danielewicz M; Hamid M; Swahn E; Henareh L; Wagner H; Hårdhammar P; Sjögren I; Stewart J; Grimfjärd P; Jensen J; Aasa M; Robertsson L; Lindroos P; Haupt J; Wikström H; Ulvenstam A; Bhiladvala P; Lindvall B; Lundin A; Tödt T; Ioanes D; Råmunddal T; Kellerth T; Zagozdzon L; Götberg M; Andersson J; Angerås O; Östlund O; Lagerqvist B; Held C; Wallentin L; Scherstén F; Eriksson P; Koul S; James S
N Engl J Med; 2017 Sep; 377(12):1132-1142. PubMed ID: 28844201
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
13. Timing of P2Y
Almendro-Delia M; Hernández-Meneses B; Padilla-Rodríguez G; Blanco-Ponce E; Arboleda-Sánchez JA; Rodríguez-Yáñez JC; Soto-Blanco JM; Fernández-García I; Castillo-Caballero JM; García-Rubira JC; Hidalgo-Urbano R
J Am Coll Cardiol; 2024 Jun; 83(25):2629-2639. PubMed ID: 38897672
[TBL] [Abstract][Full Text] [Related]
14. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
15. Tailored P2Y
Janssen PWA; Bergmeijer TO; Vos GA; Kelder JC; Qaderdan K; Godschalk TC; Breet NJ; Deneer VHM; Hackeng CM; Ten Berg JM
Eur J Clin Pharmacol; 2019 Sep; 75(9):1201-1210. PubMed ID: 31197411
[TBL] [Abstract][Full Text] [Related]
16. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
17. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.
Silvain J; Rakowski T; Lattuca B; Liu Z; Bolognese L; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimsky P; Miller D; Portal JJ; Collet JP; Vicaut E; Montalescot G; Dudek D;
J Am Coll Cardiol; 2019 Mar; 73(8):906-914. PubMed ID: 30819358
[TBL] [Abstract][Full Text] [Related]
18. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention in Patients Treated With Potent P2Y12 inhibitors - a VALIDATE-SWEDEHEART Substudy.
Bergman S; Mohammad MA; James SK; Angerås O; Wagner H; Jensen J; Scherstén F; Fröbert O; Koul S; Erlinge D
J Am Heart Assoc; 2021 Sep; 10(18):e022984. PubMed ID: 34514849
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.
Bellemain-Appaix A; Bégué C; Bhatt DL; Ducci K; Harrington RA; Roe M; Wiviott SD; Cucherat M; Silvain J; Collet JP; Bernasconi F; Montalescot G
EuroIntervention; 2018 May; 14(1):78-85. PubMed ID: 29469030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
